synagis 100 mg/ml 1 vial 0,5 ml
synagis 100 mg/ml 1 vial 1 ml
synagis 100mg injection
abbvie sdn bhd - palivizumab -
synagis 100mgml solution for injection
astrazeneca sdn. bhd. - palivizumab -
synagis solution for injection 100mgml
astrazeneca singapore pte ltd - palivizumab - injection, solution - palivizumab 100mg/ml
synagis 100mg 100 mg
مستودع أدوية حسام النمر - hussam al nmer drug store - palivizumab 100 mg - 100 mg
synagis 50mg 50 mg
مستودع أدوية حسام النمر - hussam al nmer drug store - palivizumab 50 mg - 50 mg
synadrin tablets
hoechst ireland limited - prenylamine - tablets
abbosynagis 100 mg
abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.
abbosynagis 50 mg
abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.